Executives from Varex Imaging (NASDAQ:VREX) mentioned current geopolitical occasions and tariff volatility haven’t materially modified demand developments for the corporate up to now in 2026, whereas outlining expectations for incremental margin enchancment as prior tariff prices roll by way of stock and highlighting longer-term development initiatives tied to India manufacturing growth, photon-counting CT detectors, and cargo inspection programs.
CEO Sunny Sanyal mentioned the corporate has restricted direct enterprise publicity within the Center East, together with minimal footprint in Iran, however is waiting for second-order impacts. He famous Varex makes use of vital ocean freight, although not by way of the Strait of Hormuz, and mentioned larger oil costs might elevate commodity prices. “Thus far, we’ve got not seen something of consequence but,” Sanyal mentioned.
Administration characterised the primary half of the yr as unfolding largely as anticipated and mentioned early lead indicators—significantly order consumption—have remained steady. Sanyal emphasised that Varex’s largest end-market publicity is healthcare, the place demand is pushed largely by affected person dynamics fairly than near-term macro occasions. He mentioned the corporate has not seen impacts on hospital capital budgets, nor has it heard clients “telegraph” modifications in shopping for conduct.
In response to questions in regards to the firm’s roughly 70/30 combine between medical and industrial markets, Sanyal mentioned the medical facet seems “considerably unaffected” up to now. On the commercial facet, he described non-destructive testing/inspection as additionally unaffected up to now.
On safety functions, nonetheless, Sanyal mentioned developments seem at the least “flat to optimistic,” including that the corporate is seeing “extra urgency” and elevated inquiries about its applied sciences.
Sanyal and CFO Sam Maheshwari mentioned Varex adjusted pricing and pass-through mechanisms after a pointy escalation in tariff ranges earlier within the cycle. Sanyal mentioned the corporate’s stock elevated for a number of causes, and that reductions in tariff charges haven’t but totally flowed by way of outcomes as a result of higher-tariff stock stays available.
Maheshwari mentioned present circumstances are “directionally optimistic,” however cautioned that ongoing coverage dialogue—together with potential Part 301 actions—might result in additional modifications. He mentioned Varex continues to mitigate tariff impacts by way of steps reminiscent of provide chain diversification (together with efforts to diversify extra sourcing out of India), trade-compliance methods, and continued progress towards “local-for-local” manufacturing.
On profitability, Maheshwari mentioned that if the present tariff regime stays in place, gross margin might enhance modestly as older, higher-tariff stock strikes by way of the P&L over roughly 4 to 5 months. He estimated the profit at “a couple of tens of foundation factors,” citing a potential 30 to 50 foundation level enchancment, in contrast with a beforehand mentioned 100 to 150 foundation level impression when larger tariffs had been instituted. He added that the corporate is watching what occurs when momentary tariff measures are changed.
Sanyal mentioned China’s imaging market dynamics have adopted the corporate’s expectations after a interval that included hospital audits, stimulus results that had been initially complicated, and provide chain distortions from clients buying too far forward. He mentioned China stays dedicated to increasing healthcare supply in rural markets, describing a sample the place provinces inspired hospitals with comparatively new programs to exchange them with up to date variations and redeploy displaced programs into rural settings. He referred to as that dynamic “wholesome,” saying it elevated put in base and refreshed programs.
He mentioned demand now seems “steady to possibly barely rising” and has shifted towards a extra mature replacement-driven sample, fairly than the “frenzied” development charges seen in prior durations. He added that secular development in China stays larger than the two% to three% development charges usually related to mature markets.
On aggressive positioning, Sanyal mentioned home Chinese language imaging gamers are profitable share in authorities tenders, which he mentioned have turn out to be “extraordinarily aggressive.” He added that this development has been favorable for Varex as a result of it provides a lot of these home gamers. Requested about hypothesis that enormous international OEMs may exit or promote stakes in China, Sanyal mentioned the corporate views such commentary as “largely rumour” and didn’t supply a conclusion.
Individually, Sanyal mentioned he doesn’t see a particular materials-availability concern for Varex akin to helium constraints affecting MRI programs.
Maheshwari offered updates on two India amenities. He mentioned the detector facility is full and starting to ramp, with “moderately respectable income” anticipated from India-made detectors within the second half of 2026. On tubes, he mentioned the manufacturing unit is lower than a yr away from producing product, with preliminary batches anticipated towards the tip of calendar 2026.
He mentioned each factories are designed round radiographic merchandise, an space the place Varex has had decrease market share as a result of worth sensitivity. Administration is concentrating on new merchandise manufactured in India to assist acquire share. Maheshwari mentioned the corporate expects a “considerably linear” development profile from the start of fiscal 2027 by way of the tip of fiscal 2028, concentrating on about $100 million of incremental radiographic income over roughly two years, above natural expectations.
On photon-counting CT, Sanyal described adoption as early however mentioned the know-how has confirmed viable. He mentioned preliminary deployments have emphasised excessive decision, whereas the longer-term worth is “exact materials discrimination,” together with multi-energy “spectral” imaging. He added that Varex is targeted on enabling adoption past the most important OEMs and high educational facilities. Searching to 2028, Sanyal mentioned the corporate’s purpose is to have 4 OEMs deeply engaged in design work; he mentioned Varex has two in the present day and expects extra OEMs within the pipeline, noting the corporate would really feel comfy with three and “superb” with 4 by the tip of 2028.
Maheshwari reiterated a purpose to maneuver company gross margin towards the excessive 30% vary over the subsequent few years, citing three drivers:
Photon counting, which he mentioned ought to carry gross margins above the company common and elevate general margins as adoption grows.
Cargo inspection programs, the place he mentioned service income is “considerably extra accretive” on margin because the put in base expands.
India radiographic development, which he mentioned is predicted to be nearer to corporate-average gross margin however ought to contribute significant working leverage.
Maheshwari additionally mentioned a current debt refinancing, saying the corporate decreased coupon charges by about 175 foundation factors, translating to roughly $7 million to $8 million in annual curiosity financial savings, or about $0.15 to $0.16 in annualized EPS profit. He mentioned the refinancing simplified the steadiness sheet and described the result as optimistic regardless of uneven markets.
Varex Imaging Company is a world supplier of X-ray imaging parts and options for the medical, safety and industrial markets. The corporate designs, develops and manufactures a broad vary of merchandise that convert X-ray vitality into high-resolution digital photographs. Its portfolio consists of X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and associated software program, all engineered to satisfy the demanding necessities of authentic tools producers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing functions.
The corporate’s medical imaging choices assist a large spectrum of scientific modalities, from transportable radiography programs to superior CT scanners, enhancing picture high quality and dose effectivity for healthcare suppliers.
